Adaptive Symptom Self-Management Immunotherapy Study

Launched by UNIVERSITY OF ARIZONA · Jan 27, 2023

Keywords

ClinConnect Summary

The Adaptive Symptom Self-Management Immunotherapy Study is a clinical trial looking at how to better manage symptoms that may arise during cancer treatment using immune checkpoint inhibitors (ICIs). These treatments help the immune system fight cancer but can cause side effects, known as immune-related adverse events (irAEs), which can be quite common. The goal of this study is to see if teaching patients to recognize and report their symptoms early can help manage these side effects more effectively, leading to fewer interruptions in treatment and less need for unexpected medical visits.

To participate in this trial, you should be at least 18 years old and have started ICI treatment for cancer within the last 12 weeks. You also need to be able to understand and communicate in English or Spanish and have access to a phone. If you're feeling mildly distressed—like feeling anxious, sad, or discouraged—you may be eligible. However, if you're already receiving regular counseling for behavioral issues, you won't be able to join. Participants in the study will learn how to monitor their symptoms and communicate with their healthcare team to help improve their treatment experience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older
• • Within 12 weeks after starting ICI treatment for cancer
• • Cognitively oriented to person, place and time (determined by recruiter)
• • Able to speak and understand English or Spanish
• • Access to a telephone
• • Severity score of 1 (mild) or higher on at least 1 of the 3 indicators of psychological distress from the PRO-CTCAE (i.e., the three items of anxious, discouraged, sad) library
• Exclusion Criteria:
• • Currently receiving regular behavioral counseling